Innate Pharma (IPHA) Total Debt (2017 - 2025)

Innate Pharma (IPHA) has reported Total Debt for 9 consecutive years, with $25.7 million the latest figure, recorded in Q4 2025.

• Quarterly Total Debt fell 27.17% year-over-year to $25.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.7 million (down 27.17% YoY) and the FY2025 annual result came in at $35.7 million, down 20.98% from the prior year.
• Total Debt eased to $25.7 million in Q4 2025 per IPHA's latest filing, from $30.8 million in the prior quarter.
• Over the last five years, Total Debt for IPHA reached as high as $72.3 million in Q2 2022 and fell as low as $18.8 million in Q2 2021.
• A 5-year average of $41.3 million and a median of $42.9 million in 2024 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2021 — Total Debt plunged 99.9% — and 2022, when it soared 285.15%.
• Year by year, Total Debt stood at $50.4 million in 2021, then retreated by 4.52% to $48.1 million in 2022, then decreased by 5.58% to $45.4 million in 2023, then retreated by 22.3% to $35.3 million in 2024, then decreased by 27.17% to $25.7 million in 2025.
• According to Business Quant data, Total Debt over the past three periods registered $25.7 million, $30.8 million, and $35.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.